Associations between CYP2C19 genetic polymorphisms with the risk to develop acute lymphoblastic leukemia and serum concentrations of methotrexate

Shu-mei WANG,Lu-lu SUN,Wei-xin ZENG,Guo-liang ZHANG

DOI: https://doi.org/10.13699/j.cnki.1001-6821.2014.07.006

2014-01-01

Abstract:Objective To investigate the associations between CYP2C19*2 (G681A) and CYP2C19*3 (G636A) polymorphisms with the risk to develop acute lymphoblastic leukemia ( ALL ) and serum concentra-tions of methotrexate ( MTX).Methods Peripheral blood samples were obtained from healthy subjects as control samples ( n=283 ) and children with acute lymphoblastic leukemia ( n =91 ) to extract genome DNA.Polymerase chain reaction-restriction fragment length polymorphism was used to detect the genotypes of CYP2C19*2 and CYP2C19*3 polymor-phisms.Fluorescence polarization immunoassay was employed to deter-mine the serum concentrations of MTX at the time of 24 h and 42 h.Results There were similar frequencies of genotypes and alleles at CYP2 C19*2 and CYP2 C19*3 in healthy subjects and ALL children.Compared with wid alleles , variant alleles ( A) lowered the risk of ALL , but there was no statistical difference.There were no significant differ-ences in the dose-adjusted serum concentration ( C/D ratio) of MTX at the 24 h and 42 h among respective genotype groups at CYP2 C19*2 and CYP2C19*3.Conclusion CYP2C19*2 and CYP2C19*3 polymorphisms are not associated with the risk to develop ALL and serum concentrations of MTX.